StockNews.com Downgrades Oramed Pharmaceuticals (NASDAQ:ORMP) to Sell

Oramed Pharmaceuticals (NASDAQ:ORMP) was downgraded by equities research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Wednesday.

Oramed Pharmaceuticals Trading Down 1.2 %

Shares of NASDAQ:ORMP opened at $2.37 on Wednesday. The stock has a 50 day moving average of $2.35 and a 200 day moving average of $2.37. The company has a market cap of $95.53 million, a PE ratio of 21.55 and a beta of 1.66. Oramed Pharmaceuticals has a 12-month low of $2.00 and a 12-month high of $3.67.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ORMP. World Equity Group Inc. bought a new position in Oramed Pharmaceuticals in the 4th quarter worth approximately $48,000. XTX Topco Ltd raised its holdings in shares of Oramed Pharmaceuticals by 59.7% during the 3rd quarter. XTX Topco Ltd now owns 24,716 shares of the biotechnology company’s stock worth $60,000 after acquiring an additional 9,242 shares in the last quarter. Marquette Asset Management LLC purchased a new stake in shares of Oramed Pharmaceuticals during the 4th quarter worth approximately $81,000. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Oramed Pharmaceuticals during the 3rd quarter worth approximately $272,000. Finally, Dimensional Fund Advisors LP raised its holdings in shares of Oramed Pharmaceuticals by 143.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 118,995 shares of the biotechnology company’s stock worth $288,000 after acquiring an additional 70,190 shares in the last quarter. 12.73% of the stock is currently owned by institutional investors.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.